SteriPack Global Medical Packaging Manufacturer Extends QAD Enterprise Applications Life Science Edition to New Facility in U.S.

QAD Manufacturing ERP Solution Enables SteriPack to Align Processing and Quality Standards to Regulatory Requirements

SANTA BARBARA, Calif.--()--QAD Inc. (NASDAQ: QADA (NASDAQ: QADB), a leading provider of enterprise software and services for global manufacturers, today announced SteriPack Group, a global provider in high quality medical packaging solutions, is extending its implementation of QAD Enterprise Applications Life Science Edition. With existing implementations of QAD in Ireland, Poland and Malaysia, SteriPack is now implementing QAD Enterprise Applications at its first U.S.-based operations.

“QAD Enterprise Applications offer SteriPack USA business process continuity across all of our facilities,” said Tony Paolino, president, SteriPack USA. “Extending QAD to SteriPack USA enables us to rapidly onboard new operations that can run at peak performance to deliver consistent supply to our medical device customers.”

QAD Offers the Power of Process Continuity to Global Life Science Customers

QAD Enterprise Applications provide powerful end-to-end capabilities that improve business performance across a global enterprise. Available in multiple languages with true multi-tiered on-premise QAD On Demand software as a service (SaaS) and hybrid deployment options, QAD supports the needs of global life science companies like SteriPack to deliver to consistent quality and comply with regulatory requirements regardless of deployment options.

QAD Enterprise Applications support critical quality requirements, including regulatory compliance, CAPA, and Device History/Electronic Batch Record requirements. QAD solutions can be simply validated to comply with Current Good Manufacturing Practices (cGMP). QAD provides capabilities and tools to enable SteriPack services to deliver the very highest levels of quality at all times. QAD offers enhanced controls and audit capabilities, along with eSignature support to help meet the mandate of compliance tracking.

End-to-End Multi-site Capabilities for Plant Locations and Financials

Designed for single- or multi-site operations, QAD Enterprise Applications accommodate different production models, plant locations, and financial structures for global manufacturing companies in more than 90 countries, 27 languages, and in multiple currencies.

“Today’s manufacturing companies, like SteriPack, need enterprise solutions that provide the utmost agility for the rapidly shifting global marketplace,” said Steve Gardner, EMEA vice president, sales and marketing, QAD. “QAD Enterprise Applications and QAD On Demand give medical device manufacturers a flexible, cost-effective, global ERP solution to help them bring their products to market on time, while meeting regulatory requirements and managing risk.”

To learn more about QAD Enterprise Applications for Life Sciences, visit http://www.qad.com/erp/Life-Sciences/.

About SteriPack

SteriPack is a leading global supplier of cleanroom sterilized packaging solutions for the medical device industry, offering a one-stop solution for medical device companies looking to have their products assembled, packaged, sterilized, and tested. For more information, please visit http://www.SteriPackgroup.com/.

About QAD

QAD is a leading provider of enterprise applications for global manufacturing companies specializing in automotive, consumer products, electronics, food and beverage, industrial, and life sciences products. QAD applications provide critical functionality for managing manufacturing resources and operations within and beyond the enterprise, enabling global manufacturers to collaborate with their customers, suppliers, and partners to make and deliver the right product, at the right cost, and at the right time.

For more information about QAD, telephone +1 805-566-6000, or visit the QAD web site at www.qad.com.

“QAD” is a registered trademark of QAD Inc. All other products or company names herein may be trademarks of their respective owners.

Note to Investors: This press release contains certain forward-looking statements made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expects”, “believes”, “anticipates”, “could”, “will likely result”, “estimates”, “intends”, “may”, “projects”, “should”, and variations of these words and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are based on the company’s current expectations and assumptions regarding its business, the economy, and future conditions. A number of risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements. These risks include, but are not limited to, evolving demand for the company's software products and products that operate with the company's products; the company's ability to sustain license and service demand; the company's ability to leverage changes in technology; the company's ability to sustain customer renewal rates at current levels; the publication of opinions by industry and financial analysts about the company, its products, and technology; the reliability of estimates of transaction and integration costs and benefits; the entry of new competitors or new offerings by existing competitors and the associated announcement of new products and technological advances by them; delays in localizing the company's products for new or existing markets; the ability to recruit and retain key personnel; delays in sales as a result of lengthy sales cycles; changes in operating expenses, pricing, timing of new product releases, the method of product distribution, or product mix; timely and effective integration of newly acquired businesses; general economic conditions; exchange rate fluctuations; and, the global political environment. In addition, revenue and earnings in the enterprise resource planning (ERP) software industry are subject to fluctuations. Software license revenue, in particular, is subject to variability, with a significant proportion of revenue earned in the last month of each quarter. Given the high margins associated with license revenue, modest fluctuations can have a substantial impact on net income. Investors should not use any one quarter's results as a benchmark for future performance. For a more detailed description of the risk factors associated with the company and the industries in which it operates, please refer to the company's Annual Report on Form 10-K for fiscal 2012 ended January 31, 2012, and in particular, the section entitled “Risk Factors” therein, and in other periodic reports the company files with the Securities and Exchange Commission.

Contacts

QAD Inc.
Ashley DeVan
Sr. Director of Marketing Communications
+1 805-566-6126
ashley.devan@qad.com
or
Heidi Wieland
Media Relations
+1 805-565-2452
Heidi.wieland@qad.com

Release Summary

SteriPack global medical packaging manufacturer extends QAD Enterprise Applications Life Science Edition to new facility in U.S.

Sharing

Contacts

QAD Inc.
Ashley DeVan
Sr. Director of Marketing Communications
+1 805-566-6126
ashley.devan@qad.com
or
Heidi Wieland
Media Relations
+1 805-565-2452
Heidi.wieland@qad.com